Header Logo

JOE Y CHANG

TitleProfessor
InstitutionMD Anderson
DepartmentRadiation Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rodrigues G, Higgins KA, Rimner A, Amini A, Chang JY, Chun SG, Donington J, Edelman MJ, Gubens MA, Iyengar P, Movsas B, Ning MS, Park HS, Wolf A, Simone CB. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024 Apr 11. PMID: 38602670.
      Citations:    
    2. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152. PMID: 38605064; PMCID: PMC11009351.
      Citations:    
    3. Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. [18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program. Phys Imaging Radiat Oncol. 2024 Apr; 30:100568. PMID: 38585372; PMCID: PMC10998205.
      Citations:    
    4. Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463. PMID: 38471502; PMCID: PMC10983039.
      Citations:    Fields:    Translation:Humans
    5. Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai A, Dilling TJ, Dowell J, Durm GA, Garassino MC, Gettinger S, Grotz TE, Gubens MA, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Owen D, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hang L. Mesothelioma: Pleural, Version 1.2024. J Natl Compr Canc Netw. 2024 03; 22(2):72-81. PMID: 38503043.
      Citations:    Fields:    Translation:Humans
    6. Chang JY, Verma V, Weichselbaum RR. Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal. Eur J Cancer. 2024 Apr; 201:113972. PMID: 38430868.
      Citations:    Fields:    Translation:Humans
    7. Liu W, Feng H, Taylor PA, Kang M, Shen J, Saini J, Zhou J, Giap HB, Yu NY, Sio TS, Mohindra P, Chang JY, Bradley JD, Xiao Y, Simone CB, Lin L, Liu W, Feng H, Taylor PA, Kang M, Shen J, Saini J, Giap HB, Yu NY, Sio TS, Mohindra P, Chang JY, Bradley JD, Xiao Y, Simone CB. NRG Oncology and PTCOG Patterns of Practice Survey and Consensus Recommendations on Pencil-Beam Scanning Proton Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies. Int J Radiat Oncol Biol Phys. 2024 Feb 22. PMID: 38395086.
      Citations:    Fields:    
    8. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z, Xu T. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 Apr; 193:110121. PMID: 38311031; PMCID: PMC10947851.
      Citations:    Fields:    Translation:Humans
    9. Liu W, Feng H, Taylor PA, Kang M, Shen J, Saini J, Zhou J, Giap HB, Yu NY, Sio TS, Mohindra P, Chang JY, Bradley JD, Xiao Y, Ii CBS, Lin L, Liu W, Feng H, Taylor PA, Kang M, Shen J, Saini J, Zhou J, Giap HB, Yu NY, Sio TS, Mohindra P, Chang JY, Bradley JD, Xiao Y, Simone CB, Lin L. Proton Pencil-Beam Scanning Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies: Patterns of Practice Survey and Recommendations for Future Development from NRG Oncology and PTCOG. ArXiv. 2024 Feb 01. PMID: 38351927; PMCID: PMC10862926.
      Citations:    
    10. Wisdom AJ, Barker CA, Chang JY, Demaria S, Formenti S, Grassberger C, Gregucci F, Hoppe BS, Kirsch DG, Marciscano AE, Mayadev J, Mouw KW, Palta M, Wu CC, Jabbour SK, Schoenfeld JD, Wisdom AJ, Kirsch DG, Jabbour SK, Schoenfeld JD. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1404-1421. PMID: 38184173.
      Citations:    Fields:    Translation:Humans
    11. Tate MK, Hernandez M, Chang JY, Lin SH, Liao Z, Koshy SM, Skinner HD, Chun SG. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Res. 2024 Jan; 44(1):133-137. PMID: 38159979.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081. PMID: 37728512; PMCID: PMC10566451.
      Citations:    Translation:Humans
    13. Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 09; 21(9):961-979. PMID: 37673108.
      Citations:    Fields:    Translation:Humans
    14. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881. PMID: 37478883; PMCID: PMC10529504.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    15. Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, Park HS, Rodrigues G, Wolf A, Simone CB. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol. 2023 07 01; 9(7):971-980. PMID: 37186595.
      Citations:    Fields:    Translation:Humans
    16. Al-Tashi Q, Saad MB, Sheshadri A, Wu CC, Chang JY, Al-Lazikani B, Gibbons C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Jaffray D, Mirjalili S, Wu J. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers. Patterns (N Y). 2023 Aug 11; 4(8):100777. PMID: 37602223; PMCID: PMC10435962.
      Citations: 1     
    17. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 Jul; 5(7):e404-e420. PMID: 37268451; PMCID: PMC10330920.
      Citations:    Fields:    Translation:Humans
    18. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines? Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023 04; 21(4):340-350. PMID: 37015337.
      Citations: 8     Fields:    Translation:Humans
    19. Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Cancer. 2023 07 01; 129(13):1969-1985. PMID: 36994945.
      Citations:    Fields:    Translation:Humans
    20. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540. PMID: 36716413; PMCID: PMC9928880.
      Citations:    Fields:    Translation:Humans
    21. Zhu XR, Li Y, Yang M, Whitaker TJ, Taylor PA, Zhang X, Poenisch F, Sahoo N, Liao Z, Chang JY. Stereotactic body proton therapy for early stage non-small cell lung cancer - Technical challenges and solutions: The MD Anderson experience. J Radiosurg SBRT. 2023; 9(1):75-82. PMID: 38029015; PMCID: PMC10681148.
      Citations:    
    22. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117. PMID: 36371941.
      Citations:    Fields:    
    23. Seyedin SN, Bassalow R, Mawlawi OR, Turner LM, Patel RR, Mazin SR, Oderinde OM, Voronenko Y, Wages CA, Olcott PD, Chang JY, Balter PA, Welsh JW. The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study. Front Oncol. 2022; 12:921473. PMID: 36313653; PMCID: PMC9613936.
      Citations:    
    24. Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022 11; 176:149-156. PMID: 36209942.
      Citations: 1     Fields:    Translation:Humans
    25. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. 2022 10; 23(10):1321-1331. PMID: 36087590; PMCID: PMC10618956.
      Citations:    
    26. Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, Xie C, Bi N, Hui Z, Zhu G, Yuan Z, Wang J, Zhao L, Zhou W, Rim CH, Navarro-Martin A, Vanneste BGL, Ruysscher D, Choi JI, Jassem J, Chang JY, Kepka L, K?smann L, Milano MT, Van Houtte P, Suwinski R, Traverso A, Doi H, Suh YG, No?l G, Tomita N, Kowalchuk RO, Sio TT, Li B, Lu B, Fu X. International consensus on radiotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res. 2022 Sep; 11(9):1763-1795. PMID: 36248338; PMCID: PMC9554677.
      Citations: 1     
    27. Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, Welsh JW. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):676-683. PMID: 35973624.
      Citations:    
    28. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):977-988. PMID: 35675852.
      Citations:    Fields:    
    29. Chen M, Wang Z, Jiang S, Sun J, Wang L, Sahoo N, Brandon Gunn G, Frank SJ, Xu C, Chen J, Nguyen QN, Chang JY, Liao Z, Ronald Zhu X, Zhang X. Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Sci Rep. 2022 06 02; 12(1):9178. PMID: 35655073; PMCID: PMC9163134.
      Citations:    Fields:    Translation:Humans
    30. Chang JY, Verma V. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival. J Natl Compr Canc Netw. 2022 05; 20(5):531-539. PMID: 35545175.
      Citations:    Fields:    Translation:Humans
    31. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 05; 20(5):497-530. PMID: 35545176.
      Citations: 12     Fields:    Translation:Humans
    32. Chang JY, Verma V, Welsh JW, Formenti SC. Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncol. 2022 04; 23(4):e156. PMID: 35358456.
      Citations:    Fields:    Translation:Humans
    33. Chang JY, Verma V, Weichselbaum RR. Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy. JAMA Oncol. 2022 03 01; 8(3):333-334. PMID: 34989790.
      Citations:    Fields:    Translation:Humans
    34. De Leo AN, Dagan R, Amdur RJ, Yeung AR, Li J, Brooks ED, Gilbo P, Gomez D, Chang JY, Ning M. How 3 Academic Centers Prescribe Stereotactic Body Radiation Therapy for Primary Lung Cancer. Pract Radiat Oncol. 2022 Nov-Dec; 12(6):496-503. PMID: 35219881.
      Citations:    Fields:    
    35. Wu Y, Verma V, Liang F, Lin Q, Zhou Z, Wang Z, Wang Y, Wang J, Chang JY. Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):635-644. PMID: 35196537.
      Citations:    Fields:    
    36. Knopf AC, Czerska K, Fracchiolla F, Molinelli S, Rinaldi I, Rucincki A, Trnkova P, Zhang Y, Chang JY, Giap H, Liu W, Schild SE, Simone CB, Lomax AJ, Meijers A, Graeff C, Sterpin E, St?tzer K. Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy - A comprehensive review. Radiother Oncol. 2022 04; 169:77-85. PMID: 35189152.
      Citations:    Fields:    Translation:Humans
    37. Li H, Dong L, Chang J, Flampouri S, Jee KW, Lin L, Moyers M, Mori S, Rottmann J, Tryggestad E, Vedam S, Bert C. AAPM Task Group Report 290: Respiratory motion management for particle therapy. Med Phys. 2022 Apr; 49(4):e50-e81. PMID: 35066871; PMCID: PMC9306777.
      Citations: 1     Fields:    
    38. Brooks ED, Wang X, De B, Verma V, Williamson TD, Hunter R, Mohamed ASR, Ning MS, Zhang X, Chang JY. An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone". Radiat Oncol. 2022 Jan 06; 17(1):4. PMID: 34991637; PMCID: PMC8739721.
      Citations:    Fields:    Translation:Humans
    39. Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol. 2022 Apr; 61(4):403-408. PMID: 34913815.
      Citations: 1     Fields:    Translation:Humans
    40. Chang JY, Verma V, Feng L, Roth JA. SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply. Lancet Oncol. 2021 12; 22(12):e537-e538. PMID: 34856147.
      Citations:    Fields:    Translation:Humans
    41. Chuong MD, Hallemeier CL, Li H, Zhu XR, Zhang X, Tryggestad EJ, Yu J, Yang M, Choi JI, Kang M, Liu W, Knopf A, Meijers A, Molitoris JK, Apisarnthanarax S, Giap H, Hoppe BS, Lee P, Chang JY, Simone CB, Lin SH. Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Front Oncol. 2021; 11:748331. PMID: 34737959; PMCID: PMC8560961.
      Citations:    
    42. Iyengar P, Zhang-Velten E, Court L, Westover K, Yan Y, Lin MH, Xiong Z, Patel M, Rivera D, Chang J, Saunders M, Shivnani A, Lee A, Hughes R, Gerber D, Dowell J, Gao A, Heinzerling J, Li Y, Ahn C, Choy H, Timmerman R. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01; 7(10):1497-1505. PMID: 34383006; PMCID: PMC8531992.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    43. Amini A, Verma V, Simone CB, Chetty IJ, Chun SG, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Rybkin II, Slotman BJ, Wolf A, Chang JY. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):361-375. PMID: 34571054.
      Citations: 2     Fields:    Translation:Humans
    44. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457. PMID: 34529930; PMCID: PMC8521627.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    45. Farooqi A, Ludmir EB, Mitchell KG, Antonoff MB, Tang C, Lee P, Chang J, Elamin Y, Gomez DR, Gandhi SJ. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiother Oncol. 2021 10; 163:114-118. PMID: 34419505.
      Citations: 2     Fields:    Translation:Humans
    46. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67. PMID: 34237343.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    47. Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol. 2021 07; 31(3):217-226. PMID: 34090648.
      Citations:    Fields:    Translation:Humans
    48. Chang JY. When Constrained by Constraints: Thinking Outside of the Box in Both Technology and Biology. Int J Radiat Oncol Biol Phys. 2021 06 01; 110(2):266-267. PMID: 33989570.
      Citations:    Fields:    Translation:Humans
    49. Ning MS, Das P, Rosenthal DI, Dabaja BS, Liao Z, Chang JY, Gomez DR, Klopp AH, Gunn GB, Allen PK, Nitsch PL, Natter RB, Briere TM, Herman JM, Wells R, Koong AC, McAleer MF. Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. J Natl Compr Canc Netw. 2021 04 20; 19(7):805-813. PMID: 33878727.
      Citations:    Fields:    Translation:Humans
    50. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol. 2021 May; 28:54-61. PMID: 33778173; PMCID: PMC7985216.
      Citations: 2     
    51. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021 03 02; 19(3):254-266. PMID: 33668021.
      Citations: 149     Fields:    Translation:Humans
    52. Alshawa A, Cadena AP, Stephen B, Reddy A, Mendoza TR, McQuinn L, Lawhorn K, Zarifa A, Bernhardt AM, Fessaheye S, Warneke CL, Chang JY, Naing A. Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. Invest New Drugs. 2021 08; 39(4):1113-1122. PMID: 33580845.
      Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    53. Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 09; 22(5):e745-e755. PMID: 33707003.
      Citations: 4     Fields:    Translation:Humans
    54. Verma V, Chang JY. Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era? Transl Lung Cancer Res. 2021 Jan; 10(1):5-8. PMID: 33569287; PMCID: PMC7867789.
      Citations:    
    55. Chun SG, Simone CB, Amini A, Chetty IJ, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. J Thorac Oncol. 2021 01; 16(1):66-75. PMID: 33166720.
      Citations: 6     Fields:    Translation:Humans
    56. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277. PMID: 33198942; PMCID: PMC7855203.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    57. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475. PMID: 33096027.
      Citations: 55     Fields:    Translation:Humans
    58. Vassiliev ON, Peterson CB, Chang JY, Mohan R. Monte Carlo evaluation of target dose coverage in lung stereotactic body radiation therapy with flattening filter-free beams. J Radiother Pract. 2022 Mar; 21(1):81-87. PMID: 35401050; PMCID: PMC8992779.
      Citations:    
    59. Expert Panel Thoracic Malignancies:, Higgins KA, Simone CB, Amini A, Chetty IJ, Donington J, Edelman MJ, Chun SG, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. J Thorac Oncol. 2021 01; 16(1):54-65. PMID: 33011389.
      Citations: 3     Fields:    Translation:Humans
    60. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2). PMID: 33051340; PMCID: PMC7555111.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    61. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927. PMID: 32916308; PMCID: PMC10600713.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    62. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364. PMID: 32798606; PMCID: PMC10644952.
      Citations: 6     Fields:    Translation:HumansAnimals
    63. Vassiliev ON, Peterson CB, Chang JY, Mohan R. Using FFF Beams to Improve the Therapeutic Ratio of Lung SBRT. J Radiother Pract. 2021 Dec; 20(4):419-425. PMID: 35330584; PMCID: PMC8939879.
      Citations: 1     
    64. Simone CB, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol. 2020 Jul; 30(3):253-261. PMID: 32503791; PMCID: PMC10870390.
      Citations: 3     Fields:    Translation:Humans
    65. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7. PMID: 32727706.
      Citations:    Fields:    Translation:Humans
    66. Radiotherapy-Immunotherapy Discussion Group, Ai X, Cai Y, Chu Q, Han C, Lu Y, Qin S, Wu L, Xie C, Yuan Z, Zhong W, Zhu X, Chang JY, Zhu Z. [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics]. Zhongguo Fei Ai Za Zhi. 2020 Jun 20; 23(6):532-540. PMID: 32517461; PMCID: PMC7309548.
      Citations:    Fields:    Translation:Humans
    67. Zeng J, Badiyan SN, Garces YI, Wong T, Zhang X, Simone CB, Chang JY, Knopf AC, Mori S, Iwata H, Meijers A, Li H, Bues M, Liu W, Schild SE, Rengan R, International Particle Therapy Cooperative Group Thoracic Subcommittee. Consensus Statement on Proton Therapy in Mesothelioma. Pract Radiat Oncol. 2021 Mar-Apr; 11(2):119-133. PMID: 32461036.
      Citations: 4     Fields:    Translation:Humans
    68. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol. 2020 Jul-Aug; 5(4):700-704. PMID: 32395673; PMCID: PMC7212983.
      Citations: 5     
    69. Wang Z, Chen M, Sun J, Jiang S, Wang L, Wang X, Sahoo N, Gunn GB, Frank SJ, Nguyen QN, Liao Z, Chang JY, Zhu XR, Zhang X. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol. 2020 05; 146:200-204. PMID: 32220701; PMCID: PMC10035357.
      Citations: 7     Fields:    Translation:Humans
    70. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):897-908. PMID: 32360653.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    71. McGinnis GJ, Ning MS, Nitsch PL, O'Reilly MS, McAleer MF, Koong AC, Chang JY. Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. J Thorac Oncol. 2020 06; 15(6):1085-1087. PMID: 32311499; PMCID: PMC7162784.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    72. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open. 2020 04 01; 3(4):e203277. PMID: 32320035; PMCID: PMC7177199.
      Citations: 4     Fields:    Translation:Humans
    73. Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol. 2020 04; 43(4):231-235. PMID: 31990759.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    74. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579. PMID: 32160096; PMCID: PMC7213588.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    75. Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020 08; 42(8):1939-1953. PMID: 32129548; PMCID: PMC9673070.
      Citations: 9     Fields:    Translation:Humans
    76. Nantavithya C, Gomez DR, Chang JY, Mohamed ASR, Fuller CD, Li H, Brooks ED, Gandhi SJ. An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiother Oncol. 2020 04; 145:209-214. PMID: 32062325.
      Citations: 1     Fields:    Translation:Humans
    77. Zhuang H, Tao L, Wang X, Shi S, Yuan Z, Wang E, Chang JY. Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study. Front Oncol. 2020; 10:12. PMID: 32117704; PMCID: PMC7026471.
      Citations: 3     
    78. Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 06 01; 107(2):261-269. PMID: 32044413.
      Citations: 1     Fields:    Translation:Humans
    79. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, OCN, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 12; 17(12):1464-1472. PMID: 31805526.
      Citations: 255     Fields:    Translation:Humans
    80. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    81. Brooks ED, Verma V, Senan S, Lu S, Brunelli A, Chang JY, International Association for the Study of Lung Cancer Advanced Radiation Technology Committee, De Baere T. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J Thorac Oncol. 2020 02; 15(2):176-189. PMID: 31712134; PMCID: PMC7058490.
      Citations: 7     Fields:    Translation:Humans
    82. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604. PMID: 31529018; PMCID: PMC6749545.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    83. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909. PMID: 31658994; PMCID: PMC6891218.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    84. Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107. PMID: 31627177; PMCID: PMC7043289.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    85. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273. PMID: 31605794.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    86. Kang J, Ning MS, Feng H, Li H, Brooks ED, Welsh JW, Ye R, Miao H, Chang JY, Bahig H. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):90-99. PMID: 31586665; PMCID: PMC6911622.
      Citations: 10     Fields:    Translation:Humans
    87. Brooks ED, Ning MS, Verma V, Zhu XR, Chang JY. Proton therapy for non-small cell lung cancer: the road ahead. Transl Lung Cancer Res. 2019 Sep; 8(Suppl 2):S202-S212. PMID: 31673525; PMCID: PMC6795573.
      Citations: 10     
    88. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. J Thorac Oncol. 2020 01; 15(1):101-109. PMID: 31479748.
      Citations: 12     Fields:    Translation:Humans
    89. Verma V, Ludmir EB, Mesko SM, Brooks ED, Augustyn A, Milano MT, Lin SH, Chang JY, Welsh JW. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):324-329. PMID: 31446147.
      Citations: 3     Fields:    Translation:Humans
    90. Zhuang H, Shi S, Chang JY. Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Transl Lung Cancer Res. 2019 Aug; 8(4):524-531. PMID: 31555525; PMCID: PMC6749108.
      Citations: 5     
    91. Brooks ED, Verma V, Chang JY. Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC? Front Oncol. 2019; 9:551. PMID: 31293978; PMCID: PMC6598426.
      Citations: 2     
    92. Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 07; 20(4):e480-e488. PMID: 31078421.
      Citations:    Fields:    Translation:Humans
    93. Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW, Selek U. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193. PMID: 30828330; PMCID: PMC6384252.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    94. Zhuang H, Shi S, Yuan Z, Chang JY. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer. 2019 02 07; 18(1):21. PMID: 30732625; PMCID: PMC6367784.
      Citations: 37     Fields:    Translation:HumansPHPublic Health
    95. Verma V, Haque W, Cushman TR, Lin C, Simone CB, Chang JY, McClelland S, Welsh JW. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019 Feb/Mar; 42(2):55-64. PMID: 30628924.
      Citations: 12     Fields:    Translation:Humans
    96. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019 02; 16(2):123-135. PMID: 30401936.
      Citations: 80     Fields:    Translation:Humans
    97. Videtic GM, Paulus R, Singh AK, Chang JY, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD, Parker W. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1077-1084. PMID: 30513377; PMCID: PMC6454873.
      Citations: 73     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    98. Moreno AC, Zhang N, Giordano SH, Liao Z, Gomez D, Chang JY, Lin SH. Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. Int J Part Ther. 2018; 5(2):18-27. PMID: 31773031; PMCID: PMC6874194.
      Citations:    
    99. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, Thomas CR. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018 11 23; 6(1):128. PMID: 30470252; PMCID: PMC6251215.
      Citations: 78     Fields:    Translation:Humans
    100. Vassiliev ON, Kry SF, Wang HC, Peterson CB, Chang JY, Mohan R. Radiotherapy of lung cancers: FFF beams improve dose coverage at tumor periphery compromised by electronic disequilibrium. Phys Med Biol. 2018 09 28; 63(19):195007. PMID: 30189421; PMCID: PMC6192016.
      Citations: 7     Fields:    Translation:Humans
    101. Verma V, Chang JY. Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. Transl Lung Cancer Res. 2018 Sep; 7(Suppl 3):S280-S282. PMID: 30393622; PMCID: PMC6193913.
      Citations: 2     
    102. Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390. PMID: 30646121; PMCID: PMC6324276.
      Citations: 17     Fields:    Translation:Humans
    103. Chang JY. In Reply to Hurmuz and Ozyigit. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):745. PMID: 29893286.
      Citations:    Fields:    
    104. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 07; 16(7):807-821. PMID: 30006423.
      Citations: 214     Fields:    Translation:Humans
    105. Zhang Y, Shen J, Simone CB, Cappuzzo F, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T, Written on behalf of AME Lung Cancer Cooperative Group. How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. J Thorac Dis. 2018 Jun; 10(6):3883-3890. PMID: 30069390; PMCID: PMC6051847.
      Citations: 2     
    106. Li H, Chang JY. Accounting for, Mitigating, and Choice of Margins for Moving Tumors. Semin Radiat Oncol. 2018 06; 28(3):194-200. PMID: 29933879.
      Citations: 1     Fields:    Translation:Humans
    107. Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 11 15; 24(22):5735-5743. PMID: 29784675; PMCID: PMC6239963.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    108. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2018 Apr; 7(2):199-204. PMID: 29876319; PMCID: PMC5960659.
      Citations: 1     
    109. Verma V, Chang JY. Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. J Thorac Dis. 2018 Apr; 10(Suppl 9):S1124-S1126. PMID: 29849206; PMCID: PMC5949409.
      Citations: 4     
    110. Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563. PMID: 29680255.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    111. Liu C, Schild SE, Chang JY, Liao Z, Korte S, Shen J, Ding X, Hu Y, Kang Y, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):479-489. PMID: 29550033; PMCID: PMC5935576.
      Citations: 14     Fields:    Translation:Humans
    112. Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW. Combining radiation plus immunotherapy to improve systemic immune response. J Thorac Dis. 2018 Feb; 10(Suppl 3):S468-S479. PMID: 29593892; PMCID: PMC5861265.
      Citations: 16     
    113. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922. PMID: 29386574; PMCID: PMC5792427.
      Citations: 44     Fields:    Translation:HumansCells
    114. Verma V, Chang JY. Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. J Thorac Dis. 2018 Jan; 10(1):21-24. PMID: 29600013; PMCID: PMC5863202.
      Citations: 1     
    115. Kang J, Chang JY, Sun X, Men Y, Zeng H, Hui Z. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. J Cancer. 2018; 9(3):584-593. PMID: 29483964; PMCID: PMC5820926.
      Citations: 12     
    116. de Groot PM, Shroff GS, Ahrar J, Sabloff BS, Gladish GM, Moran C, Gupta S, Gladish GW, Chang JY, Erasmus JJ. Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):139-145. PMID: 29904738; PMCID: PMC6000068.
      Citations:    
    117. Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1090-1097. PMID: 29246722.
      Citations: 23     Fields:    Translation:Humans
    118. Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol. 2017 11; 125(2):325-330. PMID: 29054376.
      Citations:    Fields:    Translation:Humans
    119. Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032. PMID: 28727865; PMCID: PMC5824219.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    120. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):58-65. PMID: 28867546.
      Citations: 18     Fields:    Translation:Humans
    121. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676. PMID: 29280461.
      Citations: 28     Fields:    Translation:Humans
    122. Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, Lu HM, Liu W, Badiyan SN, Both S, Meijers A, Lin L, Flampouri S, Li Z, Umegaki K, Simone CB, Zhu XR. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):41-50. PMID: 28816159.
      Citations: 51     Fields:    Translation:Humans
    123. Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039. PMID: 28346656; PMCID: PMC5544582.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    124. Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992. PMID: 28259750; PMCID: PMC5881570.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    125. Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly M, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280. PMID: 28139305; PMCID: PMC5319887.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    126. Khan KA, O'Connell O, Peng SA, Gomez DR, Chang JY, Rice DC, Mehran R, Jimenez CJ, Grosu HB, Ost DE, Eapen GA, Vial MR. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body?Radiotherapy Patients. Ann Thorac Surg. 2017 May; 103(5):1600-1605. PMID: 28027732; PMCID: PMC5401639.
      Citations: 9     Fields:    Translation:Humans
    127. Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907. PMID: 28258887; PMCID: PMC5881567.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    128. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27713162; PMCID: PMC5356691.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    129. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850. PMID: 27821490; PMCID: PMC5875182.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    130. Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis. 2016 Nov; 8(11):3053-3055. PMID: 28066581; PMCID: PMC5179422.
      Citations: 1     
    131. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382. PMID: 27794500.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    132. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551; PMCID: PMC5355002.
      Citations: 137     Fields:    Translation:HumansCellsCTClinical Trials
    133. Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203. PMID: 27743801.
      Citations: 18     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    134. Jiang S, Wang J, Li H, Liao L, Li Y, Wang X, Yang Y, Zhu RX, Sahoo N, Gillin MT, Hojo Y, Sun J, Chang JY, Liao Z, Grosshans D, Frank SJ, Zhang X. Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. Int J Part Ther. 2016; 3(1):37-50. PMID: 31772974; PMCID: PMC6871576.
      Citations:    
    135. Zhuang H, Yuan X, Chang JY, Song Y, Wang J, Yuan Z, Wang X, Wang P. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 2016 07 26; 7(30):48842-48849. PMID: 26934327; PMCID: PMC5217054.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    136. Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW, Brooks ED. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016 Jul-Aug; 22(4):257-66. PMID: 27441745; PMCID: PMC5812885.
      Citations: 16     Fields:    Translation:Humans
    137. Chang JY, Selek U. Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. J Thorac Dis. 2016 Jul; 8(7):1394-7. PMID: 27500390; PMCID: PMC4958859.
      Citations: 1     
    138. Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):63-71. PMID: 27637136.
      Citations: 2     Fields:    Translation:Humans
    139. Zhuang H, Yuan X, Zheng Y, Li X, Chang JY, Wang J, Wang X, Yuan Z, Wang P. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep. 2016 Apr 12; 6:24364. PMID: 27067388; PMCID: PMC4828710.
      Citations: 15     Fields:    Translation:Humans
    140. Moghanaki D, Chang JY. Is surgery still the optimal treatment for stage I non-small cell lung cancer? Transl Lung Cancer Res. 2016 Apr; 5(2):183-9. PMID: 27183993; PMCID: PMC4858582.
      Citations: 7     
    141. Khader J, Al-Mousa A, Hijla FA, Al-Heet S, Rashdan I, Balter P, Chang J, Wadi-Ramahi S. Requirements and Implementation of a Lung SBRT Program in a Developing Country: Benefits of International Cooperation. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1236-8. PMID: 27354130.
      Citations: 2     Fields:    Translation:Humans
    142. Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1226-35. PMID: 27209498.
      Citations: 23     Fields:    Translation:Humans
    143. Li R, Pu X, Chang JY, Ye Y, Komaki R, Minna JD, Roth JA, Han B, Wu X. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One. 2016; 11(3):e0150467. PMID: 26991123; PMCID: PMC4798772.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    144. Zhuang H, Yuan X, Sun D, Bian J, Chang JY, Yuan Z, Wang P. Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget. 2016 Mar 15; 7(11):13265-13268. PMID: 26933810; PMCID: PMC4914358.
      Citations: 5     Fields:    
    145. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016 08; 13(8):516-24. PMID: 26951040; PMCID: PMC6053911.
      Citations: 137     Fields:    Translation:Humans
    146. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Choy H. Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):638. PMID: 26867895.
      Citations: 17     Fields:    
    147. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016 Mar; 43(3):1111-8. PMID: 26936698.
      Citations: 21     Fields:    Translation:Humans
    148. Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW, Schoenhals JE. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7. PMID: 27111909.
      Citations: 19     Fields:    Translation:HumansCells
    149. Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu X. Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers (Basel). 2016 Feb 18; 8(2). PMID: 26901225; PMCID: PMC4773746.
      Citations: 6     
    150. Zhuang H, Zheng Y, Wang J, Chang JY, Wang X, Yuan Z, Wang P. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget. 2016 Feb 16; 7(7):7773-9. PMID: 26675376; PMCID: PMC4884953.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    151. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8. PMID: 26891607; PMCID: PMC4875833.
      Citations: 14     Fields:    Translation:Humans
    152. Xu JY, Lu S, Xu XY, Hu SL, Li B, Li WX, Chang JY. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol. 2016 Aug; 37(8):10349-56. PMID: 26846099.
      Citations: 8     Fields:    Translation:HumansCells
    153. Chang JY, Senan S, Smit EF, Roth JA. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply. Lancet Oncol. 2016 Feb; 17(2):e42-e43. PMID: 26868349.
      Citations: 2     Fields:    Translation:Humans
    154. Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS, International Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):505-516. PMID: 27084663; PMCID: PMC10868643.
      Citations: 56     Fields:    Translation:HumansPHPublic Health
    155. Prabhakar R, Oates R, Daryl J, Chang J, Geso M, Cramb J. Rectal complication probability from composite volumes derived from daily cone beam computed tomography in prostate cancer radiotherapy. J Cancer Res Ther. 2016 Jan-Mar; 12(1):374-8. PMID: 27072266.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    156. Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids. 2015 Dec 15; 4:e270. PMID: 26670277; PMCID: PMC5014539.
      Citations: 34     
    157. Liu W, Schild SE, Chang JY, Liao Z, Chang YH, Wen Z, Shen J, Stoker JB, Ding X, Hu Y, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, Bues M. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):523-533. PMID: 26725727; PMCID: PMC4834263.
      Citations: 36     Fields:    Translation:Humans
    158. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980. PMID: 26310908; PMCID: PMC4825325.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    159. Chang JY, Senan S, Smit EF, Roth JA. Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply. Lancet Oncol. 2015 Aug; 16(8):e374-5. PMID: 26248841.
      Citations: 3     Fields:    Translation:Humans
    160. Videtic GM, Hu C, Singh AK, Chang JY, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Timmerman RD, Choy H, Parker W. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):757-64. PMID: 26530743; PMCID: PMC4744654.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    161. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015 Jul; 6(4):324-31. PMID: 26094172; PMCID: PMC4536110.
      Citations: 13     Fields:    Translation:Humans
    162. Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72. PMID: 26028228; PMCID: PMC4807869.
      Citations: 36     Fields:    Translation:Humans
    163. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7. PMID: 25981812; PMCID: PMC4489408.
      Citations: 453     Fields:    Translation:HumansCTClinical Trials
    164. Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY, Expert Panel on Radiation Oncology-Lung:, Willers H. ACR Appropriateness Criteria(?) induction and adjuvant therapy for N2 non-small-cell lung cancer. Am J Clin Oncol. 2015 Apr; 38(2):197-205. PMID: 25803563.
      Citations: 4     Fields:    Translation:Humans
    165. Bezjak A, IASLC Advanced Radiation Technology Committee, Chang JY, Mornex F. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2015 Apr; 10(4):577-85. PMID: 25514807.
      Citations: 45     Fields:    Translation:Humans
    166. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015 Jun; 41(6):503-10. PMID: 25872878; PMCID: PMC4816218.
      Citations: 211     Fields:    Translation:Humans
    167. Grant JD, Shirvani SM, Tang C, Juloori A, Rebueno NC, Allen PK, Chang JY. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e383-91. PMID: 25731965.
      Citations: 4     Fields:    Translation:Humans
    168. Li H, Zhang X, Park P, Liu W, Chang J, Liao Z, Frank S, Li Y, Poenisch F, Mohan R, Gillin M, Zhu R. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015 Mar; 114(3):367-72. PMID: 25708992; PMCID: PMC4400219.
      Citations: 21     Fields:    Translation:Humans
    169. Xu JY, Lu S, Xu XY, Hu SL, Li B, Qi RX, Chen L, Chang JY. Knocking Down Nucleolin Expression Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Influencing DNA-PKcs Activity. Asian Pac J Cancer Prev. 2015; 16(8):3301-6. PMID: 25921135.
      Citations: 6     Fields:    Translation:HumansCells
    170. Chang JY. Stereotactic ablative radiotherapy: aim for a cure of cancer. Ann Transl Med. 2015 Jan; 3(1):12. PMID: 25705644; PMCID: PMC4293479.
      Citations: 3     
    171. Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014 Dec; 149(12):1244-53. PMID: 25321323; PMCID: PMC4401470.
      Citations: 91     Fields:    Translation:Humans
    172. Chang JY. Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer. Semin Radiat Oncol. 2015 Apr; 25(2):110-6. PMID: 25771415; PMCID: PMC4363100.
      Citations: 10     Fields:    Translation:Humans
    173. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56. PMID: 25442335.
      Citations: 13     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    174. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63. PMID: 25467928.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    175. Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR, Gomez DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60. PMID: 25521400; PMCID: PMC4273574.
      Citations: 26     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    176. Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):809-18. PMID: 25260491; PMCID: PMC4252731.
      Citations: 46     Fields:    Translation:Humans
    177. McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27. PMID: 25220718.
      Citations: 36     Fields:    Translation:Humans
    178. Li H, Liu W, Park P, Matney J, Liao Z, Chang J, Zhang X, Li Y, Zhu RX. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. J Appl Clin Med Phys. 2014 Sep 08; 15(5):4810. PMID: 25207565; PMCID: PMC4161985.
      Citations: 5     Fields:    Translation:Humans
    179. Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH, He L. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014 Sep; 9(9):1398-405. PMID: 25122435.
      Citations: 27     Fields:    Translation:Humans
    180. De Ruysscher D, Pijls-Johannesma M, Chang JY, Langendijk JA. The cost of setting up and operating a hadron facility. In regard to Vanderstraeten et al. Int J Radiat Oncol Biol Phys. 2014 Sep 01; 90(1):238. PMID: 25195995.
      Citations:    Fields:    Translation:Humans
    181. Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Videtic GM, Willers H. ACR Appropriateness Criteria? nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park). 2014 Aug 15; 28(8):706-10, 712, 714 passim. PMID: 25140629.
      Citations: 14     Fields:    Translation:Humans
    182. Kardar L, Li Y, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e259-68. PMID: 25407877; PMCID: PMC4399385.
      Citations: 24     Fields:    Translation:Humans
    183. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014 Aug; 112(2):256-61. PMID: 25108807.
      Citations: 34     Fields:    Translation:Humans
    184. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther. 2014 Nov; 96(5):609-15. PMID: 25054431; PMCID: PMC4206576.
      Citations: 13     Fields:    Translation:Humans
    185. Grant JD, Chang JY. Proton-based stereotactic ablative radiotherapy in early-stage non-small-cell lung cancer. Biomed Res Int. 2014; 2014:389048. PMID: 25136582; PMCID: PMC4124720.
      Citations:    Fields:    Translation:Humans
    186. Chang JY. In reply to Oskan. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1142. PMID: 25035223.
      Citations:    Fields:    Translation:Humans
    187. Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P, Zhuang H. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014 Jun; 9(6):882-5. PMID: 24828665.
      Citations: 13     Fields:    Translation:Humans
    188. Zhuang H, Zhao X, Zhao L, Chang JY, Wang P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Des Devel Ther. 2014; 8:667-75. PMID: 24936128; PMCID: PMC4047835.
      Citations: 8     Fields:    Translation:Humans
    189. Zhu Z, Liu W, Gillin M, Gomez DR, Komaki R, Cox JD, Mohan R, Chang JY. Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiat Oncol. 2014 May 06; 9:108. PMID: 24886059; PMCID: PMC4029832.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    190. Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW, Movsas B, Stinchcombe TE, Willers H, Rosenzweig KE, Expert Panel on Radiation OncologyLung, Videtic GM. ACR appropriateness Criteria? early-stage non-small-cell lung cancer. Am J Clin Oncol. 2014 Apr; 37(2):201-7. PMID: 25180631.
      Citations: 7     Fields:    Translation:Humans
    191. Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. J Thorac Dis. 2014 Apr; 6(4):348-55. PMID: 24688779; PMCID: PMC3968555.
      Citations: 4     
    192. Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. J Thorac Dis. 2014 Apr; 6(4):285-6. PMID: 24688773; PMCID: PMC3968561.
      Citations: 1     
    193. Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1120-8. PMID: 24661665.
      Citations: 79     Fields:    Translation:Humans
    194. Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res. 2014 May 01; 74(9):2476-86. PMID: 24618342; PMCID: PMC4357479.
      Citations: 44     Fields:    Translation:HumansCells
    195. Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014 Feb; 41(2):021721. PMID: 24506612; PMCID: PMC4108709.
      Citations: 38     Fields:    Translation:Humans
    196. Lin SH, Fang B, Gillin M, Mohan R, Chang JY, Zhang X. Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol. 2013 Dec; 8(12):1484-91. PMID: 24389430; PMCID: PMC3882687.
      Citations: 20     Fields:    Translation:HumansCells
    197. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R, Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):570-5. PMID: 24074931; PMCID: PMC3931127.
      Citations: 15     Fields:    Translation:Humans
    198. McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013 Oct; 109(1):38-44. PMID: 24016675.
      Citations: 27     Fields:    Translation:Humans
    199. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac ?8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8. PMID: 24016676.
      Citations: 14     Fields:    Translation:Humans
    200. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47. PMID: 23920393.
      Citations: 16     Fields:    Translation:Humans
    201. Chang JY. Oncology scan--promising strategies for the treatment of locally-advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):1-4. PMID: 23920382.
      Citations:    Fields:    
    202. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer. 2013 Nov; 82(2):252-9. PMID: 24018022; PMCID: PMC3839043.
      Citations: 29     Fields:    Translation:Humans
    203. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin. 2013 Aug; 23(3):369-81. PMID: 23931020.
      Citations: 8     Fields:    Translation:Humans
    204. Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol. 2013 Sep; 10(9):654-64. PMID: 23890874.
      Citations: 5     Fields:    Translation:Humans
    205. Hou DL, Shi GF, Gao XS, Asaumi J, Li XY, Liu H, Yao C, Chang JY. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma. Radiat Oncol. 2013 Jul 06; 8:169. PMID: 23829638; PMCID: PMC3723873.
      Citations: 10     Fields:    Translation:Humans
    206. Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10. PMID: 23798353; PMCID: PMC3775964.
      Citations: 28     Fields:    Translation:Humans
    207. Pan T, Riegel AC, Ahmad MU, Sun X, Chang JY, Luo D. New weighted maximum-intensity-projection images from cine CT for delineation of the lung tumor plus motion. Med Phys. 2013 Jun; 40(6):061901. PMID: 23718592.
      Citations: 3     Fields:    Translation:Humans
    208. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res. 2013 Jul 01; 73(13):4028-38. PMID: 23704207; PMCID: PMC3719971.
      Citations: 27     Fields:    Translation:Humans
    209. Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70. PMID: 23688815; PMCID: PMC3926094.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    210. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75. PMID: 23621168; PMCID: PMC3740061.
      Citations: 6     Fields:    Translation:Humans
    211. De Ruysscher D, Chang JY. Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol. 2013 Apr; 23(2):115-9. PMID: 23473688.
      Citations: 7     Fields:    Translation:Humans
    212. Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE, Expert Panel on Radiation Oncology-Lung. ACR Appropriateness Criteria? radiation therapy for small-cell lung cancer. Am J Clin Oncol. 2013 Apr; 36(2):206-13. PMID: 23511336.
      Citations: 3     Fields:    Translation:Humans
    213. Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H. Oligometastases/Oligo-recurrence of lung cancer. Pulm Med. 2013; 2013:438236. PMID: 23476762; PMCID: PMC3586482.
      Citations: 21     Fields:    
    214. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902. PMID: 23341526; PMCID: PMC3577951.
      Citations: 177     Fields:    Translation:HumansCTClinical Trials
    215. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013 May; 24(5):1312-9. PMID: 23300016; PMCID: PMC3629895.
      Citations: 84     Fields:    Translation:Humans
    216. Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447. PMID: 24200220; PMCID: PMC4086145.
      Citations: 7     Fields:    Translation:Humans
    217. McAleer MF, Balter P, Bucci MK, Kuruvila S, Komaki R, Chang JY. Capsular contracture of subcutaneous breast implant following hypofractionated stereotactic body radiotherapy for early stage lung cancer. J Radiosurg SBRT. 2013; 2(2):165-170. PMID: 29296356; PMCID: PMC5658889.
      Citations:    
    218. Zhang X, Fang B, Mohan R, Chang JY. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol. 2012 Nov; 105(2):250-7. PMID: 23022172; PMCID: PMC3845342.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    219. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1060-70. PMID: 22975611; PMCID: PMC3776428.
      Citations: 77     Fields:    Translation:Humans
    220. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152. PMID: 22963661; PMCID: PMC3444889.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    221. Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e69-76. PMID: 22901421; PMCID: PMC3428745.
      Citations: 20     Fields:    Translation:Humans
    222. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012 Aug 28; 7:144. PMID: 22929048; PMCID: PMC3444399.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    223. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3. PMID: 22921233.
      Citations: 21     Fields:    Translation:Humans
    224. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012; 2012:261096. PMID: 22966429; PMCID: PMC3432385.
      Citations: 49     Fields:    
    225. Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med. 2012; 2012:396592. PMID: 22900169; PMCID: PMC3413954.
      Citations: 5     Fields:    
    226. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20. PMID: 22819472; PMCID: PMC3468148.
      Citations: 5     Fields:    Translation:Humans
    227. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1558-65. PMID: 22572078; PMCID: PMC3474601.
      Citations: 33     Fields:    Translation:Humans
    228. Shirvani SM, Chang JY. Proton therapy for non-small cell lung cancer: Current evidence and future directions. Thorac Cancer. 2012 May; 3(2):99-108. PMID: 28920298.
      Citations: 1     Fields:    
    229. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1017-23. PMID: 22543216; PMCID: PMC3612879.
      Citations: 35     Fields:    Translation:Humans
    230. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1093-100. PMID: 22543217; PMCID: PMC3409930.
      Citations: 25     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    231. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol. 2011; 1:52. PMID: 22649768; PMCID: PMC3355954.
      Citations: 5     
    232. Decker RH, Langer CJ, Rosenzweig KE, Chang JY, Gewanter RM, Ginsburg ME, Kong FM, Lally BE, Videtic GM, Movsas B. ACR Appropriateness Criteria? postoperative adjuvant therapy in non-small cell lung cancer. Am J Clin Oncol. 2011 Oct; 34(5):537-44. PMID: 21946673.
      Citations: 2     Fields:    Translation:Humans
    233. Chang JY. Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. J Thorac Dis. 2011 Sep; 3(3):144-6. PMID: 22263079; PMCID: PMC3256526.
      Citations: 3     
    234. Shirvani SM, Chang JY. Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers (Basel). 2011 Sep 01; 3(3):3432-48. PMID: 24212962; PMCID: PMC3759204.
      Citations:    
    235. Grosshans D, Boehling NS, Palmer M, Spicer C, Erice R, Cox JD, Komaki R, Chang JY. Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. Pract Radiat Oncol. 2012 Jan-Mar; 2(1):41-5. PMID: 24674035.
      Citations: 6     Fields:    
    236. Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, Chang JY. The expression of HIF-1a in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep. 2012 Feb; 39(2):2021-9. PMID: 21647551.
      Citations: 33     Fields:    Translation:Humans
    237. Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer. 2011 May; 30(5):315-26. PMID: 21527064; PMCID: PMC4013396.
      Citations: 12     Fields:    Translation:Humans
    238. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7. PMID: 21489716; PMCID: PMC3465842.
      Citations: 22     Fields:    Translation:Humans
    239. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25. PMID: 21483023; PMCID: PMC3096796.
      Citations: 42     Fields:    Translation:Humans
    240. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Chang JY. A prospective evaluation of staging and target volume definition of lymph nodes by 18FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e759-65. PMID: 21470788.
      Citations: 7     Fields:    Translation:Humans
    241. Peng Y, Vedam S, Chang JY, Gao S, Sadagopan R, Bues M, Balter P. Implementation of feedback-guided voluntary breath-hold gating for cone beam CT-based stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):909-17. PMID: 21470784.
      Citations: 16     Fields:    Translation:Humans
    242. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13. PMID: 21437893; PMCID: PMC3174272.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    243. Nguyen GH, Murph MM, Chang JY. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers (Basel). 2011 Mar; 3(1):1232-52. PMID: 21603589; PMCID: PMC3095975.
      Citations: 24     
    244. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13. PMID: 21264827.
      Citations: 53     Fields:    Translation:Humans
    245. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1350-7. PMID: 21251767; PMCID: PMC3117089.
      Citations: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    246. Loo BW, Chang JY, Dawson LA, Kavanagh BD, Koong AC, Senan S, Timmerman RD. Stereotactic ablative radiotherapy: what's in a name? Pract Radiat Oncol. 2011 Jan-Mar; 1(1):38-9. PMID: 24673868.
      Citations: 15     Fields:    
    247. Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer. 2010 Oct; 29(10):843-54. PMID: 20868553.
      Citations: 9     Fields:    Translation:Humans
    248. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      Citations: 12     Fields:    Translation:Humans
    249. Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria? on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):969-74. PMID: 20813465.
      Citations: 6     Fields:    Translation:Humans
    250. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402. PMID: 20811626; PMCID: PMC2928273.
      Citations: 43     Fields:    Translation:HumansPHPublic Health
    251. Gomez DR, Chang JY. Adaptive radiation for lung cancer. J Oncol. 2011; 2011. PMID: 20814539; PMCID: PMC2931378.
      Citations: 11     
    252. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80(4):1015-22. PMID: 20615629; PMCID: PMC2952351.
      Citations: 50     Fields:    Translation:Humans
    253. Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol. 2010 Jul; 20(3):171-7. PMID: 20652085; PMCID: PMC2905742.
      Citations: 16     Fields:    Translation:Humans
    254. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6. PMID: 20542388; PMCID: PMC4093830.
      Citations: 26     Fields:    Translation:Humans
    255. Gewanter RM, Rosenzweig KE, Chang JY, Decker R, Dubey S, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Curr Probl Cancer. 2010 May-Jun; 34(3):228-49. PMID: 20541060.
      Citations: 5     Fields:    Translation:Humans
    256. Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):473-80. PMID: 20399032.
      Citations: 7     Fields:    Translation:Humans
    257. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1387-93. PMID: 20381271; PMCID: PMC3401019.
      Citations: 60     Fields:    Translation:Humans
    258. Nelson C, Balter P, Morice RC, Bucci K, Dong L, Tucker S, Vedam S, Chang JY, Starkschall G. Evaluation of tumor position and PTV margins using image guidance and respiratory gating. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1578-85. PMID: 20137865.
      Citations: 14     Fields:    Translation:Humans
    259. Liu SW, Li JM, Chang JY, Yu JM, Chen Q, Jiang QA, Mu XK, Zhao MH, Tian Y, Wei QL. A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma. J Xray Sci Technol. 2010; 18(4):443-50. PMID: 21045280.
      Citations: 5     Fields:    Translation:Humans
    260. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Jiang GL, Chang JY. GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol. 2009 Dec; 93(3):441-6. PMID: 19682760.
      Citations: 12     Fields:    Translation:Humans
    261. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):357-66. PMID: 19660879; PMCID: PMC2868090.
      Citations: 98     Fields:    Translation:HumansPHPublic Health
    262. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer. 2009 Jul 15; 115(14):3233-42. PMID: 19472405.
      Citations: 8     Fields:    Translation:Humans
    263. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8. PMID: 19458557.
      Citations: 1     Fields:    Translation:Humans
    264. Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84. PMID: 19179893.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    265. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol. 2009 Jan 30; 4:5. PMID: 19183471; PMCID: PMC2651897.
      Citations: 27     Fields:    Translation:Humans
    266. Ezhil M, Vedam S, Balter P, Choi B, Mirkovic D, Starkschall G, Chang JY. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol. 2009 Jan 27; 4:4. PMID: 19173738; PMCID: PMC2645420.
      Citations: 31     Fields:    Translation:Humans
    267. Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys. 2009 Jan 27; 10(1):14-21. PMID: 19223837; PMCID: PMC5720505.
      Citations: 35     Fields:    Translation:Humans
    268. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):967-71. PMID: 18954709; PMCID: PMC5113613.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    269. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65. PMID: 18854777; PMCID: PMC2665725.
      Citations: 21     Fields:    Translation:HumansCells
    270. Nelson C, Balter P, Morice RC, Choi B, Kudchadker RJ, Bucci K, Chang JY, Dong L, Tucker S, Vedam S, Briere T, Starkschall G. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. J Appl Clin Med Phys. 2008 Oct 30; 9(4):110-122. PMID: 19020478; PMCID: PMC5722352.
      Citations: 1     Fields:    Translation:Humans
    271. Britton KR, Starkschall G, Liu H, Chang JY, Bilton S, Ezhil M, John-Baptiste S, Kantor M, Cox JD, Komaki R, Mohan R. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):94-102. PMID: 18929448.
      Citations: 16     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    272. Gayed IW, Chang J, Kim EE, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R, Nu?ez R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008 Aug; 3(8):858-64. PMID: 18670303; PMCID: PMC4110902.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    273. Riegel AC, Chang JY, Vedam SS, Johnson V, Chi PC, Pan T. Cine computed tomography without respiratory surrogate in planning stereotactic radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):433-41. PMID: 18644683; PMCID: PMC4160118.
      Citations: 6     Fields:    Translation:Humans
    274. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, Cox JD, Chang JY. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1385-95. PMID: 18486357; PMCID: PMC3401022.
      Citations: 36     Fields:    Translation:Humans
    275. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep. 2008 May; 19(5):1071-7. PMID: 18425360.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    276. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res. 2008 May 01; 14(9):2813-23. PMID: 18451249; PMCID: PMC2387204.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    277. Kennedy MP, Jimenez CA, Chang J, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J. 2008 Apr; 31(4):902-3. PMID: 18378785.
      Citations:    Fields:    Translation:Humans
    278. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):177-86. PMID: 18303441.
      Citations: 37     Fields:    Translation:Humans
    279. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16. PMID: 17904303.
      Citations: 6     Fields:    Translation:Humans
    280. Qiao XY, Wang W, Zhou ZG, Gao XS, Chang JY. Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2008 Feb 01; 70(2):396-402. PMID: 17855004.
      Citations: 10     Fields:    Translation:Humans
    281. Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep. 2007 Sep; 18(3):645-51. PMID: 17671714.
      Citations: 2     Fields:    Translation:HumansCells
    282. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin. 2007 May; 17(2):251-9. PMID: 17626403.
      Citations: 16     Fields:    Translation:Humans
    283. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7. PMID: 17467922.
      Citations: 43     Fields:    Translation:Humans
    284. Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1349-58. PMID: 17446001.
      Citations: 35     Fields:    Translation:Humans
    285. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      Citations: 3     Fields:    Translation:Humans
    286. Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang J, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):531-40. PMID: 17398035.
      Citations: 104     Fields:    Translation:Humans
    287. Britton KR, Starkschall G, Tucker SL, Pan T, Nelson C, Chang JY, Cox JD, Mohan R, Komaki R. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1036-46. PMID: 17379442.
      Citations: 50     Fields:    Translation:Humans
    288. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):906-14. PMID: 17293240.
      Citations: 85     Fields:    Translation:Humans
    289. Nelson C, Starkschall G, Balter P, Morice RC, Stevens CW, Chang JY. Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):915-23. PMID: 17293241.
      Citations: 25     Fields:    Translation:Humans
    290. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):389-96. PMID: 17236963.
      Citations: 33     Fields:    Translation:Humans
    291. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med. 2006 Nov; 47(11):1756-62. PMID: 17079807.
      Citations: 36     Fields:    Translation:HumansPHPublic Health
    292. Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Kim EE. Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL. Eur J Nucl Med Mol Imaging. 2007 Mar; 34(3):354-62. PMID: 17021817.
      Citations: 6     Fields:    Translation:HumansAnimals
    293. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006 Sep 20; 24(27):4485-91. PMID: 16983118.
      Citations: 49     Fields:    Translation:Humans
    294. Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol. 2006 Jul; 1(6):526-31. PMID: 17409912.
      Citations:    Fields:    Translation:Humans
    295. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE, National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):548-82. PMID: 16813724.
      Citations: 56     Fields:    Translation:Humans
    296. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):117-25. PMID: 16765528.
      Citations: 78     Fields:    Translation:Humans
    297. Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. Int J Radiat Oncol Biol Phys. 2006 Jun 01; 65(2):573-86. PMID: 16690439.
      Citations: 5     Fields:    Translation:Humans
    298. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1087-96. PMID: 16682145.
      Citations: 101     Fields:    Translation:HumansPHPublic Health
    299. Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006 Apr 01; 64(5):1482-94. PMID: 16580499; PMCID: PMC1458528.
      Citations: 3     Fields:    Translation:HumansCells
    300. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9. PMID: 17409865.
      Citations: 26     Fields:    Translation:Humans
    301. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7. PMID: 16342067.
      Citations: 25     Fields:    Translation:Humans
    302. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005 Dec; 77(3):247-53. PMID: 16298001.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    303. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6657-68. PMID: 16166445; PMCID: PMC1351100.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    304. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005 Jul; 7(4):255-9. PMID: 15946583.
      Citations: 7     Fields:    Translation:Humans
    305. Wang H, Dong L, O'Daniel J, Mohan R, Garden AS, Ang KK, Kuban DA, Bonnen M, Chang JY, Cheung R. Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol. 2005 Jun 21; 50(12):2887-905. PMID: 15930609.
      Citations: 172     Fields:    Translation:Humans
    306. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8. PMID: 15867233.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    307. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8. PMID: 15837739.
      Citations: 1     Fields:    Translation:HumansCells
    308. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8. PMID: 16015542.
      Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    309. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64. PMID: 15708243.
      Citations: 36     Fields:    Translation:Humans
    310. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36. PMID: 15380576.
      Citations: 16     Fields:    Translation:Humans
    311. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R, Change JY. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1258-67. PMID: 15001271.
      Citations: 75     Fields:    Translation:Humans
    312. Yang DJ, Bryant J, Chang JY, Mendez R, Oh CS, Yu DF, Ito M, Azhdarinia A, Kohanim S, Edmund Kim E, Lin E, Podoloff DA. Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs. 2004 Mar; 15(3):255-63. PMID: 15014359.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    313. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12. PMID: 14697440.
      Citations: 13     Fields:    Translation:Humans
    314. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84. PMID: 14740977.
      Citations: 23     Fields:    Translation:Humans
    315. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther. 1998 Nov; 5(11):1538-44. PMID: 9930307.
      Citations: 8     Fields:    Translation:Animals
    316. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997 Feb 06; 14(5):561-8. PMID: 9053854.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    317. Chang JY, Xia W, Shao R, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene. 1996 Oct 03; 13(7):1405-12. PMID: 8875978.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    318. Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy going beyond local control. Cancer Journal (United States). 22:130-137.
    319. Improving cardiac dosimetry. Practical Radiation Oncology. 2:41-45.
    320. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation. International Journal of Radiation Oncology Biology Physics. 87:1-2.
    321. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. Journal of Applied Clinical Medical Physics. 15:47-56.
    322. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. Seminars in Radiation Oncology. 25:110-116.
    323. Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. Advanced Drug Delivery Reviews. 30:219-227.
    324. Erratum. International Journal of Radiation Oncology Biology Physics. 59:921.
    325. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. Journal of Thoracic Disease. 6:285-286.
    326. Acquired-resistance of bevacizumab treatment for radiation brain necrosis. Oncotarget. 7:13265-13268.
    327. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. Annals of Thoracic Surgery.
    328. Oligometastases/oligo-recurrence of lung cancer. Pulmonary Medicine.
    329. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 7:967-980.
    330. Proton therapy for non-small cell lung cancer. Thoracic Cancer. 3:99-108.
    331. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics.
    332. In regard to Vanderstraeten et al. International Journal of Radiation Oncology Biology Physics. 90:238.
    333. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Journal of Geriatric Oncology.
    334. Requirements and implementation of a lung sbrt program in a developing country. International Journal of Radiation Oncology Biology Physics. 95:1236-1238.
    335. Immunotherapy and stereotactic ablative radiotherapy (ISABR). Nature Reviews Clinical Oncology.
    336. Stereotactic ablative radiotherapy. Practical Radiation Oncology. 1:38-39.
    337. Is surgery still the optimal treatment for stage I non-small cell lung cancer?. Translational Lung Cancer Research. 5:183-189.
    338. Association between genetic variants in DNA double-strand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in non-small cell lung cancer. Cancers. 8.
    339. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Medical Physics. 43:1111-1118.
    340. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 7:84688-84694.
    341. Erratum. International Journal of Radiation Oncology Biology Physics. 94:638.
    342. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumor Biology. 1-8.
    343. Pleural tumors. 79-93.
    344. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 93:757-764.
    345. Charged particles in stereotactic radiosurgery. 135-146.
    346. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 87:2.
    347. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Scientific Reports. 6.
    348. ACR appropriateness criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer. ONCOLOGY (United States). 28.
    349. Lung Cancer.
    350. In reply to Dr. Bonger et al. International Journal of Radiation Oncology Biology Physics. 82:492.
    351. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 7:48842-48849.
    352. Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer. International Journal of Radiation Oncology Biology Physics. 68:1272.
    353. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 1.
    354. MiRNA-related genetic variations associated with radiotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. PLoS One. 11.
    355. Preface. Unknown Journal. xiii.
    356. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics.
    357. Proton Therapy. 338-352.
    358. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Practical Radiation Oncology. 7:63-71.
    359. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Molecular Therapy - Nucleic Acids. 4.
    360. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. Journal of Applied Clinical Medical Physics. 9:110-122.
    361. Proton Therapy. 271-282.
    362. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget. 7:7773-7779.
    363. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. Journal of Thoracic Disease. 6:348-355.
    364. Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer Journal (United States). 22:257-266.
    365. Stereotactic ablative radiotherapy for adrenal gland metastases. Practical Radiation Oncology.
    366. Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-Small Cell Lung Cancer. 379-389.
    367. The abscopal effect of local radiotherapy. Cancer Treatment Reviews. 41:503-510.
    368. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management.
    CHANG's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (539)
    Explore
    _
    Co-Authors (184)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _